|
|
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
| |
X4 Pharmaceuticals Inc's Tangible Leverage Ratio
XFOR's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth
In Q1 2025 X4 Pharmaceuticals Inc had stockholder deficit.
Within Biotechnology & Pharmaceuticals industry in the first quarter 2025, 70 other companies have achieved lower Tangible Leverage Ratio than X4 Pharmaceuticals Inc in the Q1 2025. While Tangible Leverage Ratio total ranking has improved so far in the first quarter 2025 to 1933, from total ranking in the fourth quarter 2024 at 3357 .
Explain Tangible Leverage Ratio?
What is XFOR Market Share?
What are XFOR´s Total Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
Tangible Leverage Ratio ▼
|
Tangible Leverage Ratio ▼
|
| XFOR Tangible Leverage Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Tangible Equity Change |
- |
- |
-36.07 % |
94.39 % |
- |
| Y / Y Total Liabilities Change |
-2.68 % |
17.65 % |
12.04 % |
60.7 % |
36.94 % |
| Tangible Leverage Ratio MRQ |
- |
- |
3.66 |
1.72 |
- |
| XFOR's Total
Ranking |
# 1933 |
# 3357 |
# 2527 |
# 946 |
# 2918 |
| Seq. Tangible Equity Change |
- |
- |
-51.92 % |
- |
- |
| Seq. Total Liabilities Change |
-12.99 % |
4.88 % |
2.03 % |
4.52 % |
5.19 % |
| Tangible Leverage Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 71 |
| Healthcare Sector |
# 416 |
| Overall Market |
# 1933 |
| Tangible Leverage Ratio Statistics |
| High |
Average |
Low |
| 106.19 |
4.9 |
0.24 |
| (Mar 31 2024) |
|
(Dec 31 2019) |
Cumulative X4 Pharmaceuticals Inc's Tangible Leverage Ratio
XFOR's Tangible Leverage Ratio for the trailling 12 Months
XFOR Tangible Leverage Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Tangible Equity TTM Growth |
-24.53 % |
-59.63 % |
-28.52 % |
1.75 % |
-19.04 % |
| Y / Y Total Liabilities TTM Growth |
18.31 % |
28.84 % |
45.57 % |
72.28 % |
70.43 % |
| Tangible Leverage Ratio TTM |
5.17 |
6.02 |
3.37 |
2.88 |
3.3 |
| Total Ranking TTM |
|
|
|
|
|
| Seq. Tangible Equity TTM Growth |
15.65 % |
-41.77 % |
-12 % |
27.36 % |
-38.14 % |
| Seq. Total Liabilities TTM Growth |
-0.63 % |
4.13 % |
2.9 % |
11.11 % |
8.22 % |
On the trailing twelve months basis During the 12 months period ending Q1 2025 company had stockholder deficit. Tangible Leverage Ratio is the average cumulative value over the last four quarters.
Among companies in the Biotechnology & Pharmaceuticals industry 70, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than X4 Pharmaceuticals Inc. While Tangible Leverage Ratio total ranking has improved so far to 12, from total ranking in previous 12 month period at 18.
Explain Tangible Leverage Ratio?
What is XFOR Market Share?
What are XFOR´s Total Liabilities?
| TTM Tangible Leverage Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 71 |
| Healthcare Sector |
# 416 |
| Within the Market |
# 1933 |
| trailing twelve months Tangible Leverage Ratio Statistics |
| High |
Average |
Low |
| 106.19 |
4.9 |
0.24 | | (Mar 31 2024) |
|
(Dec 31 2019) |
| Companies with similar Tangible Leverage Ratio in the quarter ending Mar 31 2025, within Biotechnology & Pharmaceuticals Industry | Tangible Leverage Ratio | Mar 31 2025 MRQ Total Liabilities | Mar 31 2025 MRQ Tangible Equity |
|
Date modified: 2025-05-23T09:22:02+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
